About Nosopharm

Mission

At Nosopharm our mission is to discover and develop first-in-class therapies to treat infectious diseases, especially in the context of antimicrobial resistance.

Infectious diseases are a major cause of global mortality, leading to more than 8 million deaths in 2019, before the Covid-19 pandemic crisis. In 2019 an estimated 4.95 million deaths were associated with bacterial antimicrobial resistance. The increase in antimicrobial resistance, making infections much harder to treat, represents a critical challenge for global health.

In this context, Nosopharm aims to contribute to the fight against infectious diseases, especially antimicrobial resistance, by discovering novel anti-infective therapies. Our R&D programs are based on our unique expertise in the exploitation of the bacteria Photorhabdus and Xenorhabdus.

Nosopharm’s drug discovery platform is based on these two underexplored antimicrobial-producing bacteria. Nosopharm is the only biotech company to explore the bacteria Photorhabdus and Xenorhabdus for anti-infective applications.

Our history in a few dates

Creation of Nosopharm and start of a long-term partnership with INRAE (French National Research Institute for Agriculture, Food and Environment) Discovery of NOSO-502, future first clinical candidate of the Odilorhabdins antibiotic class Discovery of the new antibiotic class ‘Odilorhabdins’ Integration into the highly selective European R&D consortium ND4BB ENABLECo-development partnership with EvotecEntry into the highly selective European R&D consortium GNA NOWSeries A fundraising of €2.4 million ($2.6 million)Granting of the NOSO-502 patent in the US 2009201120142015201720192020

Leadership

Philippe Villain-Guillot, PhD

Chief Executive Officer, co-founder

Philippe Villain-Guillot has been Nosopharm’s chief executive officer since co-founding the company in 2009. In this first entrepreneurial venture, he grew the company to include a staff of 10 high-skilled employees, established a robust IP portfolio,

dealt a collaboration agreement with a major biotech company, and successfully entered it into the highly-selective European R&D consortia ND4BB ENABLE (budget €100.7 million) and GNA NOW (budget €31.4 million) dedicated to antibacterial drug development.

Since the inception of the company, Philippe has raised €5.9 million in private equity and €10.8 million  in non-dilutive funding. Prior to co-founding Nosopharm, Philippe gained experience in medicinal chemistry at Evotec (UK) and focused on natural products at CIATEJ (Mexico). Philippe holds a PhD in medicinal chemistry from the University of Montpellier.

Maxime Gualtieri, PhD

Chief Scientific Officer, co-founder

Maxime Gualtieri is the co-founder and CSO at Nosopharm. Trained as a microbiologist, he is specialized in bacterial bioactive secondary metabolites, with a special focus on antimicrobials.

Maxime is the lead discoverer and investigator in Odilorhabdins, a novel antibiotic class under preclinical development at Nosopharm. He is the author of 23 peer-reviewed scientific articles and holds six patents in this field.

Prior to co-founding Nosopharm, he worked as a researcher in microbiology at CNRS (France) and at Selectbiotics, a French biotech company working in antibiotic drug discovery.

Maxime holds a PhD in microbiology from the University of Montpellier, France. He also graduated in business administration at IAE Montpellier, France.

Emilie Racine, PhD

Head of non-clinical development

Emilie Racine is head of medicinal chemistry at Nosopharm. She joined the company in 2013 to implement the chemistry element at Nosopharm and brought her extensive expertise in medicinal chemistry.

Since then, she has been involved in various programs from hit-to-lead through lead optimization, to development of NOSO-502, the first Odilorhabdins’ preclinical candidate.

She is an author of 14 peer-reviewed publications and four patents. Emilie is a member of the French Chemical Society and acts since 2013 as a board member of a regional section of the Society.

Emilie previously gained experience at Peakdale Chemistry Services, UK (now Concept Life Science). She holds a PhD in Organic Chemistry from the University of Grenoble, France, and has post-doc training at University of Montpellier, France, for Bayer Crop Science.

Supervisory board

j_biton-e1572943842148-244x300-1

Jacques Biton

Chairman of the Supervisory Board

Dr. Jacques Biton is a consultant with Novagreen Conseil, a specialist firm providing scientific and operational support for biotechnology, chemistry and cleantech startup

He brings with him 35 years of expertise in the pharmaceutical industry, particularly in antibiotics, and in the management and financing of biotechnology companies. He has more than 25 international patents to his name, covering applications in industrial biotechnology and chemistry.

Jacques holds an engineering degree in industrial biotechnology and an engineering doctorate in microbiology, enzymology and bioconversion from the University of Technology, Compiègne, France.

Frédéric Hammel

www.elaia.com

Frédéric Hammel is a venture partner at Elaia Partners and represents the firm on Nosopharm’s supervisory board. He is the managing director of Ethera, a spin-off from CEA (the French Alternative Energies and Atomic Energy Commission) / CNRS (the French National Center for Scientific Research) developing high-performance air quality solutions.

Frédéric has over 25 years’ experience gained in industrial companies and subsequently in technology startups. Prior to joining Ethera, Frédéric led projects in the life sciences sector, spanning therapeutic development, medical devices and diagnostics.

He is a former student of the Ecole Normale Supérieure in Paris, France, where he obtained a master’s in biology and a postgraduate diploma in pharmacology. He also has an MBA from the Collège des Ingénieurs (France).

In joining Nosopharm, he brings with him his expertise in the pharmaceutical industry and biotechnology business management. Frédéric has particular experience in fundraising from venture capital companies.

Gwenaël Hamon

www.kreaxi.com

Gwenaël began his career with the Siparex Group in 2009 in the capital innovation team, before joining the Kreaxi team in December 2012, where he is currently director of investment

He has strong expertise in technology startups, especially in health, biology and chemistry. To date, he has helped finance more than fifteen companies, two of which are now listed (Amoeba and Theranexus).

Gwenaël represents Kreaxi on the board of directors or on the supervisory board of several companies, including Nosopharm, Theranexus, Diabeloop, Fabentech and I-TEN.

Hamon has an engineering degree from the Ecole Nationale Supérieure des Arts et Métiers City? (France), and an advanced master’s degree in financial engineering from EM Lyon (France).

partners

Investors

Partnering news releases